Credit Suisse Reiterates Neutral on PTC Therapeutics, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Judah Frommer has reiterated a Neutral rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a $50 price target.
July 20, 2023 | 11:46 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
PTC Therapeutics' stock rating has been reiterated as Neutral by Credit Suisse, with a maintained price target of $50.
The reiteration of a Neutral rating by Credit Suisse indicates that the analyst believes the stock is fairly valued at its current price. The maintained price target of $50 suggests that the analyst does not foresee significant price movement in the near term. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100